Brines, M., Dunne, A. N., van Velzen, M., Proto, P. L., Ostenson, C., Kirk, R. I., . . . Dahan, A. (2015). ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Mol Med.
Style de citation ChicagoBrines, Michael, et al. "ARA 290, a Nonerythropoietic Peptide Engineered From Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes." Mol Med 2015.
Style de citation MLABrines, Michael, et al. "ARA 290, a Nonerythropoietic Peptide Engineered From Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes." Mol Med 2015.
Attention : ces citations peuvent ne pas être correctes à 100%.